In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
|Articles|September 2, 2021
Pii Hires Roberto Almodóvar Febles as Head of Aseptic Operations
Author(s)BioPharm International Editors
Febles will oversee day-to-day aseptic manufacturing at Pharmaceutics International, Inc.
Advertisement
PharmaceuticsInternational, Inc. (Pii) announced in an Aug. 31, 2021 press release that Roberto Almodóvar Febles has been hired as their Head of Aseptic Operations. In this role, Febles will oversee and manage day-to-day aseptic manufacturing. He will work closely with Sam Chia, the head of aseptic manufacturing science and technology, as well as the operations leadership team members.
Prior to joining Pii, Febles worked with Baxter Healthcare, Amgen, iPR Pharmaceuticals (the CMO for AstraZeneca), and Mylan. He earned a Bachelors of Science in both Chemistry and Chemical Engineering at the University of Puerto Rico, Mayagüez Campus, and an Executive Master degree in Business Administration from the Interamerican University of Puerto Rico, Cupey Campus.
“Roberto is an experienced manufacturing leader with more than 15 years of progressive experience in aseptic manufacturing as an operator, supervisor, and manager,” said Kurt Nielsen, CEO of Pii, in a company press release. “I am confident Roberto and the other teams will work to successfully deliver on-time, and right first time, for our clients."
Advertisement
Related to this article
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Detalimogene voraplasmid produced a 56% complete response rate in BCG-unresponsive bladder cancer, with an estimated 43% of responses lasting a year.
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
Gene-corrected nula-cel freed all 3 RESTORE patients from transfusions, with sickle hemoglobin below 20% in the 2 followed for over 6 months.
Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.
Matt Truppo, Richard Jaenisch, and Brian Drapeau examine AI's impact on drug success, human oversight, data governance, and biopharma's future.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
4
Beam's Risto-cel Meets Primary Endpoint in Sickle Cell Trial
5